Technology
Business
Pharmaceuticals
Profit
CMS Business
GDS Business
Speciality Segment
Peptides
High Risk
High Margin
Prime Segment
#Neuland (FY-21 Annual Report) :
- Focused on growing CMS business ; 4-5 late stage projects to get commercialised in next 12-24 Months.
- GDS business can grow with addition of specialised, high value APIs in Speciality segment. (Semaglutide)
- Focused on growing CMS business ; 4-5 late stage projects to get commercialised in next 12-24 Months.
- GDS business can grow with addition of specialised, high value APIs in Speciality segment. (Semaglutide)
GDS Business :
- Plans to launch 18 new products in phases during this decade.
- 3 Peptides at various stages of development for GDS business.
- The specialty segment is expected to drive profits and prime segment is expected to strengthen the vertical in the coming future.
- Plans to launch 18 new products in phases during this decade.
- 3 Peptides at various stages of development for GDS business.
- The specialty segment is expected to drive profits and prime segment is expected to strengthen the vertical in the coming future.
CMS Business :
- High Risk High Margin business with less competition
- Inflow of late-stage projects, having potential to boost revenue in the next fiscal.
- Peptides : Some molecules are at an advanced stage of development & show considerable promise for commercialisation.
- High Risk High Margin business with less competition
- Inflow of late-stage projects, having potential to boost revenue in the next fiscal.
- Peptides : Some molecules are at an advanced stage of development & show considerable promise for commercialisation.
Research & Development :
- 300-member strong team of research scientists.
- Filed 2 USDMF during FY-21 ; Ready to file 5 more DMFs.
- Added a new peptide lab and non-GMP Kilo lab for Unit-III
- Committed to develop high value molecules.
- 300-member strong team of research scientists.
- Filed 2 USDMF during FY-21 ; Ready to file 5 more DMFs.
- Added a new peptide lab and non-GMP Kilo lab for Unit-III
- Committed to develop high value molecules.
Supply Chain Risk :
- Earlier ~ 60% of raw materials were coming from China, whereas from June 2021 less than 10% of raw materials will be imported from China.
- Focus on in-house manufacture of some of the intermediates at Unit-III.
- Earlier ~ 60% of raw materials were coming from China, whereas from June 2021 less than 10% of raw materials will be imported from China.
- Focus on in-house manufacture of some of the intermediates at Unit-III.
Loading suggestions...